Navigation Links
VIVUS Provides Regulatory Update on QNEXA
Date:9/15/2011

pected to include four distinct medical and pharmacy claim databases.  

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy or FORTRESS; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to cond
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
2. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
3. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
4. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
5. VIVUS to Present at Three Upcoming Investor Conferences in March
6. VIVUS Provides Regulatory Update on QNEXA NDA
7. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
8. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
9. VIVUS to Present at Two Upcoming Investor Conferences
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe , ... , today announced that it now offers the revolutionary ... CPAPs are the first sleep apnea therapy devices with ... and easy to track and share real-time data on ... of their CPAP therapy.  In addition, the internal modem ...
(Date:9/30/2014)... Sept. 30, 2014 Valeant Pharmaceuticals International, Inc. ... announced that the company,s Bridgewater, New Jersey ... U.S. Food and Drug Administration (FDA) relating to an ... regards to Sculptra Aesthetic injectable, which was divested to ... the management of Valeant,s contract manufacturers (rather than Valeant,s ...
(Date:9/30/2014)... 2014 BioStructures, LLC has been awarded ... Tissue Banks (AATB), it was announced today by ... Accreditation follows an intensive nine-month process, including ... inspector.  It establishes that the level of medical, ... or exceeds the standards set by the AATB.  ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Biostructures, LLC Earns AATB Accreditation 2
... Patients For Over a Decade, SAN FRANCISCO, ... benefit from arthroscopic surgery long term,according to a ... for Sports Medicine Specialty Day at The Moscone ... surgery, rather than conservative,methods, yielded excellent results., ...
... LARGO, Fla., March 7 AlphaMed Pharmaceuticals,Corporation announced ... version of the therapeutic protein alpha 1-antitrypsin (AAT).,AlphaMed ... production system in yeast. The yeast has been ... that which is,manufactured by the human body., ...
Cached Medicine Technology:Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term 2Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term 3AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin 2
(Date:9/30/2014)... 30, 2014 A group of Americans is ... an epidemic that, left unchecked, could create a catastrophic, global ... headed to Africa. John Rogers, the Executive Director the Eugene ... to fight a disease most think mankind conquered long ago: ... years ago is on the comeback in several countries - ...
(Date:9/30/2014)... 2014 Two revolutionary procedures now being utilized ... gum disease a far less painful and far more ... you’ve ever felt electric shock waves surge through your teeth ... beverage, it’s possible you already know the impact of receding ... general dentist in West Palm Beach, and a Fellow in ...
(Date:9/30/2014)... (HealthDay News) -- Medicare should cover low-dose computed tomography ... the disease, a coalition of more than 60 patient ... the Lung Cancer Alliance, the Society of Thoracic Surgeons, ... and the American Society of Clinical Oncology, made its ... Centers for Medicare & Medicaid Services (CMS). Such ...
(Date:9/30/2014)... Defense has made progress in reducing the stigma associated ... and post-traumatic stress disorder, but more improvement is still ... Despite efforts of both the Defense Department and the ... service members still do not seek needed care for ... concerted effort to promote treatment as a way to ...
(Date:9/30/2014)... that causes a rare premature aging disease could lead ... unstoppable cell division that makes cancer so deadly. ... U-M Health System recently discovered a protein mutation that ... hematopoietic stem cells can,t regenerate and make new blood. ... cancer and bone marrow failure. , But the ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2
... Nutrition Month(R), and Cabot Creamery Cooperative(R) offers, ... they age, CABOT, Vt., Feb. 19 March ... Dietetic Association,s campaign to promote,the importance of eating a ... to eat better, smarter and,healthier. Research by the US ...
... Harvard-Trained Cosmetic and Laser,Surgeon and Board Certified ... Relations to spearhead her PR campaign. Dr. Jacob,Director ... performs a variety of medical procedures and services, ... A veteran in the field, Dr. Jacob works ...
... Hyperactivity Disorder in ... Throughout Asia -, NEW HAVEN, Conn. and KORTRIJK, ... specialty pharmaceuticals company,focused on bringing proprietary medicines to the ... announced that RHEI has,licensed from MethaPharma the exclusive right ...
... Feb. 18 The following was,released today by ... Ambulance diversion? Crowded,emergency departments? Reports and articles over ... longer emergency department wait times (in,excess of 12 ... than one,third of area hospitals were to divert ...
... An international team of scientists led by a University ... into the realm of consciousness. , The scientists have ... perception, by showing how single neurons in the human ... of Leicester bioengineer Dr Rodrigo Quian Quiroga is spearheading ...
... atrial fibrillation, analysis shows , , MONDAY, Feb. 18 (HealthDay ... that are prescribed to lower cholesterol levels may also ... that boosts the odds of a stroke, French researchers ... more than 3,500 participants showed that those patients who ...
Cached Medicine News:Health News:Hey Boomers, Here's to Your Health! 2Health News:Hey Boomers, Here's to Your Health! 3Health News:Hey Boomers, Here's to Your Health! 4Health News:Hey Boomers, Here's to Your Health! 5Health News:Dr. Carolyn Jacob Hires Empower Public Relations 2Health News:RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia 2Health News:RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia 3Health News:Gilbert Hospital Turns the Tables on the Flu 2Health News:Scientists explore consciousness 2Health News:Scientists explore consciousness 3Health News:Cholesterol-Lowering Drugs May Ease Irregular Heartbeat 2Health News:Cholesterol-Lowering Drugs May Ease Irregular Heartbeat 3
... spinal procedures. The SpineAssist platform for enhancing ... solution that enables surgery to be performed ... currently answers a growing need for accurate ... pedicle screw insertion for spine fusion procedures. ...
ACRYSOF®, Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are i...
Single piece PMMA lens, AC depth: 4.7....
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
Medicine Products: